| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Tango Therapeutics (NASDAQ:TNGX) reported its Q4 earnings results on Monday, March 18, 2024 at 07:00 AM.
Here's what investors need to know about the announcement.
Tango Therapeutics missed estimated earnings by -14.000000000000002%, reporting an EPS of $-0.32 versus an estimate of $-0.28.
Revenue was down $980 thousand from the same period last year.
Last quarter the company beat on EPS by $0.11 which was followed by a 6.0% drop in the share price the next day.
Here's a look at Tango Therapeutics's past performance:
| Quarter | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 |
|---|---|---|---|---|
| EPS Estimate | -0.34 | -0.34 | -0.35 | -0.35 |
| EPS Actual | -0.23 | -0.23 | -0.32 | -0.33 |
| Revenue Estimate | 7.32M | 6.95M | 6.71M | 6.44M |
| Revenue Actual | 10.73M | 14.60M | 5.77M | 6.41M |
** Listen to the earnings announcement yourself by clicking here. **
To track all earnings releases for Tango Therapeutics visit their earnings calendar here.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: TNGX
